Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
249.34 USD | -1.14% |
|
-1.13% | +9.03% |
10/06 | ResMed CEO Sells Shares Worth $2 Million | MT |
07/06 | Resmed Insider Sold Shares Worth $494,640, According to a Recent SEC Filing | MT |
Fiscal Period: June | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 11.63 | 12.31 | 12.73 | 12.15 | 12.7 | |||||
Return on Total Capital | 14.17 | 15.34 | 15.71 | 14.42 | 15.11 | |||||
Return On Equity % | 27.21 | 17.63 | 24.96 | 23.96 | 22.7 | |||||
Return on Common Equity | 27.21 | 17.63 | 24.96 | 23.96 | 22.7 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 59.77 | 59.1 | 57.68 | 56.5 | 57.38 | |||||
SG&A Margin | 22.88 | 20.97 | 20.66 | 20.7 | 19.57 | |||||
EBITDA Margin % | 31.21 | 32.19 | 31.42 | 30.6 | 32.73 | |||||
EBITA Margin % | 28.67 | 29.67 | 28.94 | 28.4 | 30.65 | |||||
EBIT Margin % | 27.36 | 28.7 | 27.96 | 27.28 | 29.54 | |||||
Income From Continuing Operations Margin % | 21.02 | 14.84 | 21.78 | 21.25 | 21.79 | |||||
Net Income Margin % | 21.02 | 14.84 | 21.78 | 21.25 | 21.79 | |||||
Net Avail. For Common Margin % | 21.02 | 14.84 | 21.78 | 21.25 | 21.79 | |||||
Normalized Net Income Margin | 15.79 | 17.26 | 16.99 | 16.16 | 17.78 | |||||
Levered Free Cash Flow Margin | 19.51 | 25.29 | 3.28 | 9.84 | 25.29 | |||||
Unlevered Free Cash Flow Margin | 20.36 | 25.76 | 3.67 | 10.54 | 25.95 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.68 | 0.69 | 0.73 | 0.71 | 0.69 | |||||
Fixed Assets Turnover | 6.41 | 5.67 | 5.85 | 6.52 | 6.87 | |||||
Receivables Turnover (Average Receivables) | 5.78 | 5.76 | 5.83 | 6.31 | 6.08 | |||||
Inventory Turnover (Average Inventory) | 3.1 | 2.99 | 2.3 | 1.84 | 1.87 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.53 | 1.73 | 2.8 | 3.12 | 2.59 | |||||
Quick Ratio | 1.57 | 1.04 | 1.27 | 1.29 | 1.18 | |||||
Operating Cash Flow to Current Liabilities | 1.33 | 0.81 | 0.51 | 0.91 | 1.54 | |||||
Days Sales Outstanding (Average Receivables) | 63.27 | 63.33 | 62.57 | 57.83 | 60.23 | |||||
Days Outstanding Inventory (Average Inventory) | 117.92 | 122 | 158.52 | 197.94 | 195.69 | |||||
Average Days Payable Outstanding | 36.62 | 37.08 | 28.53 | 26.6 | 38.42 | |||||
Cash Conversion Cycle (Average Days) | 144.57 | 148.24 | 192.56 | 229.16 | 217.51 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 52.03 | 27.51 | 27.3 | 38.26 | 17.97 | |||||
Total Debt / Total Capital | 34.22 | 21.57 | 21.45 | 27.67 | 15.23 | |||||
LT Debt/Equity | 50.7 | 26.27 | 26.36 | 37.48 | 17.24 | |||||
Long-Term Debt / Total Capital | 33.35 | 20.6 | 20.7 | 27.11 | 14.62 | |||||
Total Liabilities / Total Assets | 45.57 | 38.97 | 34.05 | 38.83 | 29.22 | |||||
EBIT / Interest Expense | 20.04 | 38.25 | 44.83 | 24.31 | 27.84 | |||||
EBITDA / Interest Expense | 23.51 | 44.37 | 51.97 | 27.98 | 31.67 | |||||
(EBITDA - Capex) / Interest Expense | 21.15 | 40.09 | 45.93 | 25.45 | 29.66 | |||||
Total Debt / EBITDA | 1.37 | 0.75 | 0.79 | 1.19 | 0.56 | |||||
Net Debt / EBITDA | 0.88 | 0.44 | 0.56 | 1.01 | 0.4 | |||||
Total Debt / (EBITDA - Capex) | 1.52 | 0.83 | 0.9 | 1.31 | 0.59 | |||||
Net Debt / (EBITDA - Capex) | 0.98 | 0.49 | 0.63 | 1.11 | 0.43 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 13.44 | 8.11 | 11.93 | 18.02 | 10.95 | |||||
Gross Profit, 1 Yr. Growth % | 15.02 | 6.91 | 9.24 | 15.61 | 12.67 | |||||
EBITDA, 1 Yr. Growth % | 22.58 | 11.5 | 9.27 | 14.73 | 18.69 | |||||
EBITA, 1 Yr. Growth % | 25.22 | 11.88 | 9.17 | 15.62 | 19.74 | |||||
EBIT, 1 Yr. Growth % | 27.21 | 13.41 | 9.01 | 14.95 | 20.15 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 53.65 | -23.67 | 64.26 | 15.15 | 13.75 | |||||
Net Income, 1 Yr. Growth % | 53.65 | -23.67 | 64.26 | 15.15 | 13.75 | |||||
Normalized Net Income, 1 Yr. Growth % | 26.49 | 18.21 | 10.15 | 12.01 | 22.12 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 52.5 | -24.12 | 63.58 | 14.91 | 13.63 | |||||
Accounts Receivable, 1 Yr. Growth % | -10.07 | 29.15 | -3.77 | 22.4 | 18.78 | |||||
Inventory, 1 Yr. Growth % | 19.24 | 9.62 | 83.45 | 34.06 | -12.85 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 38.26 | 10.53 | 6.49 | 5.6 | 5.01 | |||||
Total Assets, 1 Yr. Growth % | 11.68 | 3.07 | 7.78 | 32.49 | 1.79 | |||||
Tangible Book Value, 1 Yr. Growth % | -151.77 | 256.51 | 90.79 | -25.14 | 90.28 | |||||
Common Equity, 1 Yr. Growth % | 20.5 | 15.56 | 16.46 | 22.89 | 17.78 | |||||
Cash From Operations, 1 Yr. Growth % | 74.76 | -8.17 | -52.34 | 97.44 | 102.11 | |||||
Capital Expenditures, 1 Yr. Growth % | 38.74 | 7.74 | 31.27 | -11.25 | -16.89 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 36.24 | 40.17 | -84.95 | 225.3 | 195.78 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 35 | 36.78 | -83.47 | 214.18 | 181.11 | |||||
Dividend Per Share, 1 Yr. Growth % | 4 | 1.92 | 5.66 | 4.76 | 9.09 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 12.41 | 10.75 | 10 | 14.93 | 14.43 | |||||
Gross Profit, 2 Yr. CAGR % | 13.91 | 10.89 | 8.06 | 12.38 | 14.13 | |||||
EBITDA, 2 Yr. CAGR % | 18.23 | 16.91 | 10.38 | 12.06 | 16.69 | |||||
EBITA, 2 Yr. CAGR % | 20.22 | 18.36 | 10.52 | 12.45 | 17.66 | |||||
EBIT, 2 Yr. CAGR % | 20.17 | 20.12 | 11.19 | 12.05 | 17.52 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 40.35 | 8.3 | 11.97 | 37.53 | 14.45 | |||||
Net Income, 2 Yr. CAGR % | 40.35 | 8.3 | 11.97 | 37.53 | 14.45 | |||||
Normalized Net Income, 2 Yr. CAGR % | 16.4 | 22.28 | 14.11 | 11.19 | 16.96 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 39.63 | 7.57 | 11.41 | 37.1 | 14.27 | |||||
Accounts Receivable, 2 Yr. CAGR % | -1.31 | 7.77 | 11.48 | 8.53 | 17.97 | |||||
Inventory, 2 Yr. CAGR % | 24.56 | 14.33 | 42.89 | 56.82 | 8.09 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 17.72 | 23.62 | 8.49 | 6.05 | 5.3 | |||||
Total Assets, 2 Yr. CAGR % | 22.36 | 7.29 | 5.4 | 19.5 | 16.13 | |||||
Tangible Book Value, 2 Yr. CAGR % | -54.77 | 35.86 | 160.81 | 19.51 | 19.35 | |||||
Common Equity, 2 Yr. CAGR % | 10.12 | 18.01 | 16.01 | 19.63 | 20.3 | |||||
Cash From Operations, 2 Yr. CAGR % | 26.04 | 26.68 | -33.84 | -2.99 | 99.76 | |||||
Capital Expenditures, 2 Yr. CAGR % | 23.42 | 22.26 | 18.93 | 7.94 | -14.11 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 5.93 | 38.19 | -54.92 | -27.01 | 204.63 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 6.41 | 35.89 | -53.3 | -25.16 | 193.01 | |||||
Dividend Per Share, 2 Yr. CAGR % | 4.81 | 2.96 | 3.77 | 5.21 | 6.9 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 12.68 | 10.96 | 11.14 | 12.61 | 13.59 | |||||
Gross Profit, 3 Yr. CAGR % | 13.72 | 11.52 | 10.34 | 10.52 | 12.47 | |||||
EBITDA, 3 Yr. CAGR % | 17.5 | 15.95 | 14.3 | 11.87 | 14.23 | |||||
EBITA, 3 Yr. CAGR % | 18.98 | 17.37 | 15.22 | 12.26 | 14.83 | |||||
EBIT, 3 Yr. CAGR % | 21 | 17.87 | 16.29 | 12.5 | 14.69 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 22.01 | 14.56 | 24.43 | 13.02 | 29.1 | |||||
Net Income, 3 Yr. CAGR % | 22.01 | 14.56 | 24.43 | 13.02 | 29.1 | |||||
Normalized Net Income, 3 Yr. CAGR % | 18.26 | 17 | 18.1 | 13.48 | 14.72 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 21.17 | 13.95 | 23.7 | 12.56 | 28.78 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.42 | 7.95 | 3.78 | 15.01 | 10.23 | |||||
Inventory, 3 Yr. CAGR % | 15.82 | 19.37 | 34.53 | 39.88 | 28.93 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 10.76 | 15.27 | 17.62 | 7.52 | 5.7 | |||||
Total Assets, 3 Yr. CAGR % | 9.77 | 15.56 | 7.45 | 13.75 | 13.28 | |||||
Tangible Book Value, 3 Yr. CAGR % | -36.99 | -9.98 | 52.14 | 72.04 | 39.55 | |||||
Common Equity, 3 Yr. CAGR % | 8.4 | 11.91 | 17.49 | 18.26 | 19.01 | |||||
Cash From Operations, 3 Yr. CAGR % | 24.67 | 13.41 | -8.54 | -4.75 | 23.9 | |||||
Capital Expenditures, 3 Yr. CAGR % | 15.28 | 17.96 | 25.2 | 7.88 | -1.07 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 33.55 | 16.3 | -34.8 | -10.4 | 14.97 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 32.33 | 15.7 | -33.48 | -9.59 | 15.24 | |||||
Dividend Per Share, 3 Yr. CAGR % | 5.2 | 3.84 | 3.85 | 4.1 | 6.49 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 11.99 | 11.7 | 11.6 | 12.53 | 12.44 | |||||
Gross Profit, 5 Yr. CAGR % | 11.81 | 12.12 | 11.42 | 11.86 | 11.84 | |||||
EBITDA, 5 Yr. CAGR % | 13.86 | 14.51 | 14.6 | 14.37 | 15.29 | |||||
EBITA, 5 Yr. CAGR % | 15.2 | 15.58 | 15.52 | 15.38 | 16.23 | |||||
EBIT, 5 Yr. CAGR % | 14.6 | 16.05 | 16.97 | 15.51 | 16.83 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 11.99 | 6.13 | 17.89 | 23.25 | 20.34 | |||||
Net Income, 5 Yr. CAGR % | 11.99 | 6.13 | 17.89 | 23.25 | 20.34 | |||||
Normalized Net Income, 5 Yr. CAGR % | 11.37 | 14.58 | 16.58 | 14.64 | 17.68 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 11.57 | 5.41 | 17.17 | 22.7 | 19.84 | |||||
Accounts Receivable, 5 Yr. CAGR % | 5.95 | 10.35 | 5.96 | 8.18 | 9.24 | |||||
Inventory, 5 Yr. CAGR % | 11.05 | 15.28 | 25.97 | 33.54 | 23.25 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 6.68 | 9.03 | 9.85 | 11.49 | 12.53 | |||||
Total Assets, 5 Yr. CAGR % | 16.02 | 7.74 | 8 | 17.12 | 10.84 | |||||
Tangible Book Value, 5 Yr. CAGR % | -34.1 | 10.98 | 11.22 | 0.82 | 38.06 | |||||
Common Equity, 5 Yr. CAGR % | 9.48 | 11.23 | 11.38 | 14.94 | 18.61 | |||||
Cash From Operations, 5 Yr. CAGR % | 15.93 | 6.1 | -3.24 | 6.54 | 25.01 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.81 | 11.9 | 16.73 | 13.84 | 7.68 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 17.47 | 14.82 | -13.49 | -4.17 | 22.85 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 18.15 | 14.84 | -12.76 | -3.5 | 22.21 | |||||
Dividend Per Share, 5 Yr. CAGR % | 6.85 | 5.27 | 4.63 | 4.39 | 5.06 |
- Stock Market
- Equities
- RMD Stock
- Financials ResMed, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition